狄诺塞麦治疗什么病症

(Denosumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody with high specificity and affinity for RANKL. RANK receptor signaling promotes osteolysis and tumor growth.

Denosumab (denosumab) is a RANKL inhibitor that can be used for: 1. Prevention of bone-related events caused by bone metastasis of multiple myeloma and solid tumors. 2. Treatment of giant cell tumor of bone in adults or skeletally mature adolescents whose unresectable or surgical resection would lead to serious complications. 3. Treatment of bisphosphonate-resistant hypercalcemia.

Compared with bisphosphonates that have been clinically used for a long time, denosumab (desosumab) has the advantage of significantly prolonging the occurrence time of bone damage-related events; it can be administered subcutaneously and is easy to use, and clinical data shows that the drug does not require monitoring of renal function, while the use of bisphosphonates must be based on the patient's renal function monitoring to determine the dosing rate. degree; however, denosumab (desosomeb) is currently relatively expensive, and the balance between its long-term efficacy and cost-effectiveness needs to be further confirmed. It is expected that denosumab (desosomeb), a drug that specifically targets RANK ligand inhibitors, can obtain more valuable research results in the treatment of solid tumors and bring new hope to patients with bone metastasis.

The most common adverse reactions of denosumab (desosumab) reported in clinical trials were back pain in 34.7%, limb pain in 11.7%, musculoskeletal pain in 7.6%, hypercholesterolemia in 7.2%, and cystitis in 5.9%. The most common adverse reactions leading to discontinuation were breast cancer, back pain, and constipation. Other common adverse reactions include: anemia 3.3%, angina pectoris 2.6%, atrial fibrillation 2.0%, dizziness 5.0%, abdominal pain 3.3%, flatulence 2.2%, gastroesophageal reflux disease 2.1%, peripheral edema 4. 9%, weakness 2.3%, upper respiratory tract infection 4.9%, pneumonia 3.9%, pharyngitis 2.3%, herpes zoster 2.0%, spinal osteoarthritis 2.1%, sciatica 4.6%, insomnia 3.2%, rash 2.5%, and pruritus 2.2%. These adverse reactions can be overcome and require medical treatment when necessary.

Overall, the therapeutic effect of (Denosumab) is good.

Recommended related hot articles: /newsDetail/77989.html